These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10223941)

  • 21. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
    Savic RM; Lu Y; Bliven-Sizemore E; Weiner M; Nuermberger E; Burman W; Dorman SE; Dooley KE
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3035-42. PubMed ID: 24614383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
    Brooks KM; George JM; Pau AK; Rupert A; Mehaffy C; De P; Dobos KM; Kellogg A; McLaughlin M; McManus M; Alfaro RM; Hadigan C; Kovacs JA; Kumar P
    Clin Infect Dis; 2018 Jul; 67(2):193-201. PubMed ID: 29415190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM
    Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342
    [No Abstract]   [Full Text] [Related]  

  • 25. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
    Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
    Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
    Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
    Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
    Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
    Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R; Holland D; Feng PJ; Millet JP; Caylà JA; Martinson NA; Wright A; Chen MP; Moro RN; Scott NA; Arevalo B; Miró JM; Villarino ME; Weiner M; Borisov AS;
    Ann Intern Med; 2017 Nov; 167(10):689-697. PubMed ID: 29114781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
    Winter H; Egizi E; Murray S; Erondu N; Ginsberg A; Rouse DJ; Severynse-Stevens D; Pauli E
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1219-24. PubMed ID: 25512422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
    Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
    Lam E; Schaefer J; Zheng R; Zhan T; Kraft WK
    Clin Transl Sci; 2020 Nov; 13(6):1244-1250. PubMed ID: 32407548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
    Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
    Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.
    Conte JE; Golden JA; McQuitty M; Kipps J; Lin ET; Zurlinden E
    Antimicrob Agents Chemother; 2000 Apr; 44(4):985-90. PubMed ID: 10722501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
    Dorman SE; Nahid P; Kurbatova EV; Phillips PPJ; Bryant K; Dooley KE; Engle M; Goldberg SV; Phan HTT; Hakim J; Johnson JL; Lourens M; Martinson NA; Muzanyi G; Narunsky K; Nerette S; Nguyen NV; Pham TH; Pierre S; Purfield AE; Samaneka W; Savic RM; Sanne I; Scott NA; Shenje J; Sizemore E; Vernon A; Waja Z; Weiner M; Swindells S; Chaisson RE; ;
    N Engl J Med; 2021 May; 384(18):1705-1718. PubMed ID: 33951360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
    Langdon G; Wilkins JJ; Smith PJ; McIlleron H
    Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
    Phaisal W; Albitar O; Chariyavilaskul P; Jantarabenjakul W; Wacharachaisurapol N; Ghadzi SMS; Zainal H; Harun SN
    J Antimicrob Chemother; 2024 Jun; 79(6):1270-1278. PubMed ID: 38661209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
    Dutta NK; Alsultan A; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1535-7. PubMed ID: 23295923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.